Aurobindo Pharma Q3 Results: Profit and revenue jump; announces interim dividend
The board also approved an interim dividend of 150 per cent, i.e. INR 1.5 per equity share of INR 1/- for the year FY23-24.
Aurobindo Pharma's EBITDA before Forex and other income stood at Rs 1,601 crore, while EBITDA margin was 21.8 per cent. Photo: File/Representational